Mercy BioAnalytics Raises $41M in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy

Natick, MA, April 3, 2023 (Business Wire) -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series A financing round. The oversubscribed financing was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, and Broadway Angels, an all-women venture capital group. The round also included strategic investments from Labcorp and Bruker, in addition to strong participation from existing investors.

Read full article here.